Skip to content

Study · Animal study (in vivo) · mouse · 2022

2 results

Sex-Specific Differences in Gsα-Mediated Signaling Downstream of PTH1R Activation by Abaloparatide in Bone.

Swami S, Johnson J, Vecchi LA, Kim MJ, Lanske B, Johnson RW, Wu JY

JBMR plus24 Nov 2022

PMID36530190 (opens in a new tab)PMCIDPMC9751656 (opens in a new tab)DOI10.1002/jbm4.10695 (opens in a new tab)PepBankPUB-36530190
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Teriparatide, recombinant parathyroid hormone (PTH[1-34]), and abaloparatide, an analogue of PTH related-peptide (PTHrP[1-34]), are both anabolic medications for osteoporosis that target the PTH receptor PTH1R. PTH1R is a G protein-coupled receptor, and the stimulatory Gs protein is an important mediator of the anabolic actions of PTH1R activation in bone. We have published that mice lacking the α subunit of Gs in osteoprogenitors do not increase bone mass in response to PTH(1-34). Unexpectedly, however, PTH(1-34) still increases osteoblast numbers and bone formation rate in male mice, suggesting that PTH1R may have both Gs-dependent and -independent actions in bone. Here we examine the role of Gs signaling in the anabolic actions of abaloparatide. We find that abaloparatide increases bone formation in male mice with postnatal deletion of Gsα in Osx-expressing osteoprogenitors (P-GsαOsxKO mice) but not in female P-GsαOsxKO mice. Therefore, abaloparatide has anabolic effects on bone in male but not female mice that appear to be independent of Gs-mediated signaling. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Abaloparatide increased bone formation in male mice with Gsα deletion in osteoprogenitors.

    In plain wordsIn male mice with a specific gene deletion, abaloparatide increased bone formation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone formation in male knockout mice
    Study

    mousen: not reported in source

    Postnatal Gsα deletion in Osx-expressing osteoprogenitors
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We find that abaloparatide increases bone formation in male mice with postnatal deletion of Gsα in Osx-expressing osteoprogenitors (P-GsαOsxKO mice) but not in female P-GsαOsxKO mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    Abaloparatide did not increase bone formation in female mice with Gsα deletion in osteoprogenitors.

    In plain wordsIn female mice with a specific gene deletion, abaloparatide did not increase bone formation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBone formation in female knockout mice
    Study

    mousen: not reported in source

    Postnatal Gsα deletion in Osx-expressing osteoprogenitors
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We find that abaloparatide increases bone formation in male mice with postnatal deletion of Gsα in Osx-expressing osteoprogenitors (P-GsαOsxKO mice) but not in female P-GsαOsxKO mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.